Echinacea Safety Study

A. Vogel AG

Status and phase: Completed; Phase 4

Conditions: Infections

Treatments: Drug: placebo; Drug: echinacea

Study type: Interventional

Funder types: Industry

Identifiers

NCT01021995

920'134

Details and patient eligibility

About

Extracts produced from Echinacea purpurea are traditionally used for the prevention and the acute treatment of influenzal infections like the common cold. The aim of this clinical study is to assess clinical safety and efficacy of a treatment with Echinacea in comparison to placebo. 750 healthy subjects with a history of equal or more than 2 cold episodes per year will be recruited during October and November 2009 and will be treated with either Echinacea or placebo over a period of 4 months.

Throughout the study period adverse events (AEs) and adverse drug reactions (AEs with at least a possible causal relation to the treatment) will be recorded.

Common cold related symptoms will be recorded in a daily diary.

Enrollment: 757 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• On average more than 2 cold episodes per year
• Age above 18 years
• Good physical condition
• Signed informed consent

Exclusion criteria

• Women without appropriate and effective contraception
• Participation in a clinical trial 30 days prior to this trial
• Pregnant or breast feeding women
• Subjects with pre-existing cold symptoms for more than 24h at inclusion
• Concurrent participation in another clinical trial
• Intake of antimicrobial and/or antiviral medications at inclusion
• Alcohol and/or drug abuse, narcotic drug addiction before and during trial (more than 50 gr and / or 10 cigarettes per day)
• Psychiatric disorders which may influence the results of the trial,
• epilepsy, suicide attempts
• Planned surgical intervention during the trial.
• Serious chronic diseases which influence the absorption, metabolism and the elimination of the investigational product, especially progressive systemic illnesses like tuberculosis, leukaemia,
• collagen disorders and multiple sclerosis
• Known AIDS, HIV-infections and autoimmune diseases
• Known diabetes mellitus (type 1)
• Corticosteroid-treated asthma
• Atopic and allergic subjects (under medicinal treatment)
• Known allergy to plants of the composite family (Asteraceae)

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

757 participants in 2 patient groups, including a placebo group

echinacea

Experimental group

Treatment:

Drug: echinacea

placebo

Placebo Comparator group

Treatment:

Drug: placebo